Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes

BACKGROUND: Current national estimates for acute myelogenous leukemia (AML) indicate this disease accounts for 1.1% of new cancer diagnoses and 1.8% of cancer deaths in the United States. The 5-year overall survival rate for patients with AML was 27.4% between 2008 and 2014. The standard induction f...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Am Health Drug Benefits
Hlavní autoři: Jensen, Ivar S., Wu, Elizabeth, Sacks, Naomi C., Cyr, Philip L., Chung, Karen C.
Médium: Artigo
Jazyk:Inglês
Vydáno: Engage Healthcare Communications, LLC 2018
Témata:
Business
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6306103/
https://ncbi.nlm.nih.gov/pubmed/30647825
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky